Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin + azacitidine + venetoclax as first-line treatment for fit older adults with AML
ChiCTR2300070190Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idarubicin, azacitidine and venetoclax in acute myeloid leukemia (AML), sponsored by Ruijin Hospital. Primary endpoints: Complete remission rate and Duration of remission. Started Sep 2022; status: recruiting.
02
Drugs
idarubicinazacitidinevenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2300070190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070190.